Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIM NASDAQ:AVDL NASDAQ:ELVN NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/AAVDLAvadel Pharmaceuticals$11.08+5.4%$9.78$6.38▼$17.30$1.07B1.47986,045 shs993,392 shsELVNEnliven Therapeutics$18.73-0.4%$20.68$13.30▼$30.03$922.99M0.93376,154 shs490,125 shsPRAXPraxis Precision Medicines$54.09-0.2%$47.05$26.70▼$91.83$1.10B2.62443,884 shs637,762 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%-0.36%AVDLAvadel Pharmaceuticals+5.42%+0.45%+25.77%+27.50%-32.19%ELVNEnliven Therapeutics-0.43%-11.65%-9.25%-8.68%-29.00%PRAXPraxis Precision Medicines-0.24%-8.66%+16.77%+34.42%-6.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals2.6698 of 5 stars3.52.00.00.03.41.70.6ELVNEnliven Therapeutics2.5067 of 5 stars3.52.00.00.01.74.20.0PRAXPraxis Precision Medicines2.5506 of 5 stars4.41.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/AAVDLAvadel Pharmaceuticals 3.00Buy$18.3365.46% UpsideELVNEnliven Therapeutics 3.00Buy$41.20119.97% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$94.1173.99% UpsideCurrent Analyst Ratings BreakdownLatest ALIM, PRAX, ELVN, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.007/18/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$22.007/18/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.007/8/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.007/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30AVDLAvadel Pharmaceuticals$194.45M5.51N/AN/A$0.77 per share14.39ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/APRAXPraxis Precision Medicines$8.55M128.87N/AN/A$23.90 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/AAVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A184.67N/A-13.58%-36.07%-16.30%8/7/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)Latest ALIM, PRAX, ELVN, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ELVNEnliven Therapeutics-$0.54N/AN/AN/AN/AN/A8/12/2025Q2 2025PRAXPraxis Precision Medicines-$3.40N/AN/AN/A$0.16 millionN/A8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02N/AN/AN/A$60.28 millionN/A5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62AVDLAvadel PharmaceuticalsN/A2.732.33ELVNEnliven TherapeuticsN/A21.0721.06PRAXPraxis Precision MedicinesN/A8.448.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%AVDLAvadel Pharmaceuticals69.19%ELVNEnliven Therapeutics95.08%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%AVDLAvadel Pharmaceuticals5.20%ELVNEnliven Therapeutics25.90%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionableALIM, PRAX, ELVN, and AVDL HeadlinesRecent News About These CompaniesWhat to Expect from Praxis Precision Medicine's EarningsAugust 2 at 9:54 AM | benzinga.comY Intercept Hong Kong Ltd Makes New $237,000 Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)July 31 at 4:41 AM | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)July 30 at 8:26 AM | marketbeat.comPraxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT ...July 30 at 4:31 AM | bakersfield.comBPraxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial ResultsJuly 30 at 4:31 AM | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Given "Buy" Rating at Chardan CapitalJuly 30 at 3:03 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $94.11 Consensus PT from BrokeragesJuly 26, 2025 | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 23, 2025 | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A ...July 19, 2025 | finanznachrichten.dePraxis Precision Gets FDA's Breakthrough Designation for Seizure TreatmentJuly 18, 2025 | marketwatch.comPraxis Precision Medicines (NASDAQ:PRAX) Earns Buy Rating from HC WainwrightJuly 18, 2025 | marketbeat.comPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for ...July 17, 2025 | bakersfield.comBPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic EncephalopathiesJuly 17, 2025 | globenewswire.comBrokers Offer Predictions for PRAX Q1 EarningsJuly 16, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 10.4% on Analyst UpgradeJuly 9, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $115.00 at OppenheimerJuly 8, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule ...July 2, 2025 | gurufocus.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comFormer head trader of Denver-based investing company pleads guilty to insider tradingJune 9, 2025 | finance.yahoo.comWeston man pleads guilty to insider trading offense that made him $220KJune 8, 2025 | stamfordadvocate.comSPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALIM, PRAX, ELVN, and AVDL Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Avadel Pharmaceuticals NASDAQ:AVDL$11.08 +0.57 (+5.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.02 -0.05 (-0.50%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Enliven Therapeutics NASDAQ:ELVN$18.73 -0.08 (-0.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.72 -0.02 (-0.08%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Praxis Precision Medicines NASDAQ:PRAX$54.09 -0.13 (-0.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$51.76 -2.33 (-4.31%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
